XLIFE SCIENCES AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32 CHF | -2.74% |
|
-3.90% | -35.87% |
| 23/04 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
| 29/02 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 800K 868K 72.47M | Sales 2025 * | - | Capitalization | 183M 198M 16.53B |
|---|---|---|---|---|---|
| Net income 2024 * | -4M -4.34M -362M | Net income 2025 * | - | EV / Sales 2024 * | 310 x |
| Net Debt 2024 * | 65.2M 70.76M 5.91B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-48.5
x | P/E ratio 2025 * |
-
| Employees | 17 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.74% | ||
| 1 week | -3.90% | ||
| Current month | -28.89% | ||
| 1 month | -28.89% | ||
| 3 months | -34.02% | ||
| 6 months | -17.74% | ||
| Current year | -35.87% |
1 week
31.50
35.50
1 month
31.5045.00
Current year
31.5051.40
1 year
28.6051.40
3 years
23.3052.00
5 years
23.3052.00
10 years
23.3052.00
| Managers | Title | Age | Since |
|---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 01/19/01 |
Carl von Halem
DFI | Director of Finance/CFO | - | 01/21/01 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 12/19/12 |
Mark Müller
BRD | Director/Board Member | - | 25/18/25 |
Oliver Baumann
CEO | Chief Executive Officer | - | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 32 | -2.74% | 7,267 |
| 29/24/29 | 32.9 | -4.08% | 4,213 |
| 26/24/26 | 34.3 | -.--% | 4,112 |
| 25/24/25 | 34.3 | -0.29% | 2,751 |
| 24/24/24 | 34.4 | -1.43% | 4,517 |
Delayed Quote Swiss Exchange, April 30, 2024 at 09:01 pm IST
More quotes
Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Calendar
28/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32
CHF
Average target price
68
CHF
Spread / Average Target
+112.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.87% | 199M | |
| +0.17% | 42.19B | |
| +10.92% | 42.24B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B |
- Stock Market
- Equities
- XLS Stock
